Overall, there is an urgent need to better understand the downstream effects of anti-TNF drugs on the intestinal microbiome in patients with SpA, RA, and IBD and whether these changes could be used as non-invasive biomarkers of treatment response. Here, TNF is linked to inflammatory bowel disease.